Safety and efficacy of ESD combined with chemoradiotherapy in the treatment of superficial esophageal squamous cell carcinoma with ESD extended indications

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047820

Enrollment

Unknown

Registered

2021-06-27

Start date

2021-06-30

Completion date

Unknown

Last updated

2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Superficial esophageal squamous cell carcinoma

Interventions

ESD+CRT group:ESD+CRT

surgery group:surgery

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Pathologically confirmed as superficial esophageal squamous cell carcinoma; 2. Aged 18 to 80 years; 3. The thoracic surgeon and oncologist have assessed that surgery cannot be performed; 4. Sign the written informed consent; 5. Be able to receive regular follow-up visits.

Exclusion criteria

Exclusion criteria: 1. Imaging studies of CT or PET/CT have any evidence of metastasis; 2. Previous history of endoscopic treatment or esophagectomy or radiotherapy and chemotherapy; 3. Combined with serious diseases of other organs; 4. ASA rated persons with contraindications to anesthesia.

Design outcomes

Primary

Measure	Time frame
Disease specific survival rate;	—

Secondary

Measure	Time frame
mortality;Recurrence rate;Lymph node metastasis rate;Complete resection rate;	—

Countries

China

Contacts

Public ContactChai Ningli

Chinese PLA General Hospital

chainingli@vip.163.com+86 15011362982

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026